Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/221281
COMPARTIR / EXPORTAR:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Invitar a revisión por pares abierta
Título

The atypical cannabinoid Abn-CBD reduces inflammation and protects liver, pancreas, and adipose tissue in a mouse model of prediabetes and non-alcoholic fatty liver disease

AutorRomero-Zerbo, Silvana Y.; García-Fernández, María; Espinosa-Jímenez, Vanesa; Pozo-Morales, Macarena; Escamilla-Sánchez, Alejandro; Sánchez-Salido, Lourdes; Lara, Estrella; Cobo-Vuilleumier, Nadia CSIC ORCID; Rafacho, Alex; Olveira, Gabriel; Rojo-Martínez, Gemma; Gauthier, Benoit R. CSIC ORCID; González-Mariscal, Isabel; Bermúdez-Silva, Francisco Javier
Fecha de publicación2020
EditorFrontiers Media
CitaciónFrontiers in Endocrinology 11: 103 (2020)
Resumen[Background and Aims]: The synthetic atypical cannabinoid Abn-CBD, a cannabidiol (CBD) derivative, has been recently shown to modulate the immune system in different organs, but its impact in obesity-related meta-inflammation remains unstudied. We investigated the effects of Abn-CBD on metabolic and inflammatory parameters utilizing a diet-induced obese (DIO) mouse model of prediabetes and non-alcoholic fatty liver disease (NAFLD).
[Materials and Methods]: Ten-week-old C57Bl/6J mice were fed a high-fat diet for 15 weeks, following a 2-week treatment of daily intraperitoneal injections with Abn-CBD or vehicle. At week 15 mice were obese, prediabetic and developed NAFLD. Body weight and glucose homeostasis were monitored. Mice were euthanized and blood, liver, adipose tissue and pancreas were collected and processed for metabolic and inflammatory analysis.
[Results]: Body weight and triglycerides profiles in blood and liver were comparable between vehicle- and Abn-CBD-treated DIO mice. However, treatment with Abn-CBD reduced hyperinsulinemia and markers of systemic low-grade inflammation in plasma and fat, also promoting white adipose tissue browning. Pancreatic islets from Abn-CBD-treated mice showed lower apoptosis, inflammation and oxidative stress than vehicle-treated DIO mice, and beta cell proliferation was induced. Furthermore, Abn-CBD lowered hepatic fibrosis, inflammation and macrophage infiltration in the liver when compared to vehicle-treated DIO mice. Importantly, the balance between hepatocyte proliferation and apoptosis was improved in Abn-CBD-treated compared to vehicle-treated DIO mice.
[Conclusions]: These results suggest that Abn-CBD exerts beneficial immunomodulatory actions in the liver, pancreas and adipose tissue of DIO prediabetic mice with NAFLD, thus protecting tissues. Therefore, Abn-CBD and related compounds could represent novel pharmacological strategies for managing obesity-related metabolic disorders.
Versión del editorhttps://doi.org/10.3389/fendo.2020.00103
URIhttp://hdl.handle.net/10261/221281
DOI10.3389/fendo.2020.00103
E-ISSN1664-2392
Aparece en las colecciones: (CABIMER) Artículos




Ficheros en este ítem:
Fichero Descripción Tamaño Formato
atypidisea.pdf2,13 MBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo

CORE Recommender

PubMed Central
Citations

11
checked on 10-mar-2024

SCOPUSTM   
Citations

21
checked on 22-mar-2024

WEB OF SCIENCETM
Citations

19
checked on 26-feb-2024

Page view(s)

117
checked on 28-mar-2024

Download(s)

121
checked on 28-mar-2024

Google ScholarTM

Check

Altmetric

Altmetric


Artículos relacionados:


Este item está licenciado bajo una Licencia Creative Commons Creative Commons